Loree JM, et al. - Researchers investigated the benefit of adjuvant chemotherapy (AC) in patients with pathologic stage II rectal cancer (RC), using a multi-institutional database. They also assessed if outcomes were influenced by the addition of oxaliplatin to fluoropyrimidine (OXAC) therapy in these patients. The focus was on disease-free survival and overall survival. They also constructed multivariate Cox models adjusting for age, sex, Eastern Cooperative Oncology Group, high-risk features (pT4, poor differentiation, <12 nodes removed, lymphovascular/perineural invasion, or obstruction/perforation), and clinical stage. No benefit of AC following neoadjuvant chemoradiation (nCRT) was found in this multi-institutional cohort of yp stage II RC patients. Relative to fluoropyrimidine alone, no improved outcomes appeared to be provided by the addition of oxaliplatin.